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Abstract - Celiac Disease (CeD) is an immunemediated inflammatory disorder of the small intestine,
affecting genetically susceptible individuals when
exposed to gluten. Small intestinal biopsy
interpretation has been the "gold standard" for celiac
disease (CeD) for over 50 years. Despite today's
availability of sensitive and specific serological tests,
the histopathological features from mucosal biopsy
play a key role in diagnosing when CeD is suspected.
Such a diagnostic approach requires a
multidisciplinary team to optimize both tissue
sampling and interpretation via the interaction
between the pathologist and the gastroenterologist.
Pathologists of the Italian Group of Gastrointestinal
Pathology (GIPAD-SIAPEC), together with a
member (TR) of the Italian Society of Technicians
(AITIC) and an expert gastroenterologist (CC),
provide position statements as a practical tool for
reading and interpreting the report.
Moreover, a position statement was formulated
about the recently described condition known as NonCeliac Gluten Sensitivity (NCGS). Within such a
diagnostic
setting,
both
the
architectural
abnormalities of the duodenal mucosa, namely
glandular hyperplasia, and villous atrophy and the
number of intraepithelial T-lymphocytes should be
well highlighted. Ancillary tests such as anti-CD3
stain are useful for an accurate count of the

intraepithelial T lymphocytes when CeD or NCGS is
suspected. Moreover, anti-CD3 and anti-CD8 stains
are recommended in patients not responding to the
gluten-free diet (GFD) to confirm a diagnosis of
Refractory Celiac Disease (RCeD). Diagnostic clues
about the differential diagnosis of both CeD and
RCeD have also been rendered.
Keywords: histopathology, celiac disease, non-celiac
gluten sensitivity, refractory celiac disease, ulcerative
jejunitis, enteropathy-type T-cell
I. INTRODUCTION
Celiac disease (CeD) is an immune-mediated
inflammatory disorder of the small intestine, affecting
genetically susceptible individuals when exposed to gluten
[1]. Although sensitive and specific serological tests are
nowadays available, a multidisciplinary approach to the
clinical, serological, genetic, and histological features is
recommended for the diagnosis of CeD. The prevalence of
CeD is actually estimated to range from 0,2 to 1 worldwide,
but it still remains largely underdiagnosed [2-3] or
diagnosed with a significant delay [4-7]. The growing
shreds of evidence about diagnostic problems and pitfalls
make necessary the formulation of position statements
about the interpretation of the microscopic report, as to
offer a practical and useful tool for pathologists and the
non-specialized physicians. The major diagnostic
hallmarks are here discussed and reviewed by a selected
group of pathologists belonging to the Italian Group of
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Gastrointestinal Pathology (GIPAD-SIAPEC), with the
collaboration of both an expert gastroenterologist (CC) and
a member (TR) of the Italian Society of Technicians
(AITIC), in order to define diagnostic key-points to provide
a thorough histopathological report.

II. METHODOLOGY
The authors have reviewed the available
literature about CeD diagnosis, using the MeSH Terms
"anatomy and histology," "duodenum," and "celiac
disease" and/or "diagnosis." The research produced 1323
papers, of which 984 according to the aim of the present
study.
After the selection of the English language, and
the exclusion of commentaries and meeting abstracts, the
Authors evaluated 630 papers. Finally, they selected 60
papers, which included some recent guidelines that formed
the bibliographic core of our study. The methodological
approach to duodenal biopsy, the currently available
serological and genetic tests, the histological features of
both healthy and pathological duodenal mucosa, the
differential diagnosis of CeD and its complications were
critically reviewed in several meetings and teleconferences.
As a result, the methodological approach to duodenal
biopsy was summarized in eight position statements about
the serological and genetic test records accompanying the
samples, the histological features of both healthy and
pathological duodenal mucosa, the differential diagnosis
and complications of CeD. Moreover, the current
knowledge about NCGS histology was also reviewed. The
evidence levels of eight position statements were graduated
according to the Guidelines of the Oxford Center for
Evidence-Based Medicine (Oxford UK) and were
discussed by all the working parties.

III. RESULTS
Table 1 shows a synoptic view of the eight position
statements.
STATEMENT 1. A methodological approach to
duodenal biopsy.
At least six mucosal biopsies are recommended, and
biopsy orientation is strongly encouraged in order to
avoid diagnostic pitfalls. [Grade of Evidence: 2]
Patients with familiarity, previous diagnosis of CeD [8], or
clinical evidence of CeD [9,10] usually undergo an
endoscopic evaluation with duodenal mucosa biopsies.
However, it is not to be excluded that a routine endoscopy
could recognize duodenal mucosal damage when CeD is
clinically not suspected [11]. A correct evaluation of the
mucosal damage should take I into account whether at the
time of endoscopy, the diet regimen of the patient is free or
not [12]. At least four to six mucosal pinch biopsies (2 from
the bulb and 4 for the distal duodenum) are recommended
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to avoid diagnostic pitfalls or, at least, a reduced sensitivity,
particularly in children (Figure 1 A and B).
During the endoscopy, a single pinch biopsy for any
passage is recommended [1-13,14,15,16]. Biopsy
orientation could be relevant for a proper histological
assessment, although no widely validated methods are
accepted yet. Moreover, the application of this method
requires endoscopists and endoscopic staff motivated and
aware of the purposes of the method as well as an expert
laboratory technician on the different steps necessary in
order to reach optimal workout. In our experience, we
found helpful using cellulose acetate filters with a "clarinet
beak-shaped cut" (Fig.1) because they guarantee the correct
orientation of the biopsies during all phases of the sampling
preparations (Fig.2).

STATEMENT 2. Serological and genetic tests.
The record of specific CeD serology, if known, should
preferably accompany the histologic sample. The
detection of serum anti-tissue transglutaminase IgA
(TTGA) titer + IgG is the recommended serological test
for screening/case finding. The anti-endomysial IgA
search (EmA) is considered as a confirmatory test, and
its determination is necessary for patients with low (<2
x) titer TTGA. The detection of anti-gliadin antibodies
(AGA) titer together with negative TTGA and EmA
titers never qualifies CeD in adult patients and in
children. The detection of serum anti-deamidated
gliadin peptides
(DPG) IgA and IgG may also be useful, especially in
very young children. The detection of the IgG class of
TTG EmA and DPG should be limited to patients with
selective IgA deficiency. The genetic test for HLA DQ2DQ8 supports the multidisciplinary diagnosis of CeD in
selected cases, and if negative, it strongly excludes the
diagnosis of CeD. [Grade of Evidence: 3]
Availability of a serology report will boost the pathologists
to the full description of intestinal mucosa findings.
In brief, IgA class anti-transglutaminase (TTGA)
antibodies have the highest sensitivity for CeD (98%) with
an estimated specificity of about 90%. IgA class antiendomysium antibodies (EmA), although presenting a
lower sensitivity compared to the IgA class TTGA (90%
vs. 98%), show an absolute specificity for CeD. However,
IgA anti-gliadin antibodies (AGA) are now an obsolete test
with lower sensitivity and specificity for CeD.
The genetic tests play a role in supporting the diagnosis of
CeD, for the association of the disease with the
histocompatibility antigens HLA DQ2-DQ8. The genetic
test is indicated when the serological and histological data
are discrepant, in first degree relatives for the evaluation of
genetic predisposition to CeD. The main clinical role of the
genetic test in the diagnosis, however, is to exclude CeD
when HLA-DQ2- DQ8 alleles are absent [8,9,10,11,12,13].
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STATEMENT 3. The healthy duodenal mucosa.
The healthy duodenal mucosa is characterized by a
villus/crypt ratio of more than 3/1. An amount of less
than 25 intra-epithelial lymphocytes (IELs)/100
epithelial cells have to be considered not pathological.
[Grade of Evidence: 2]
The healthy duodenal mucosa is characterized by folds, in
which digitiform structures (villi) and pits (crypts)
alternate, with a villus/crypt ratio of more than 3/1. In the
lamina propria, a bland inflammatory infiltrate, composed
by lymphocytes, plasma cells, eosinophils, histiocytes,
mast cells can be found. Neutrophils are generally absent,
with the exception of the active duodenitis with gastric
metaplasia, related to Helicobacter Pylori (HP) infection.
Lymphocytes may be seen forming scattered lymphoid
aggregates in the lamina propria as well as within epithelial
cells of the duodenal mucosa, i.e., intraepithelial
lymphocytes (IEL). The presence of eosinophils, not
exceeding 5/HPF, is not considered a pathological finding.
The IELs count is a diagnostic key-point. The finding of
more than 25 IELS/100 enterocytes should be considered
unequivocally pathological, even in the regular duodenal
mucosa, suggesting early CeD. In these cases, the use of
CD3 immunostaining could be useful to avoid
misdiagnoses, allowing the more accurate count of T intraepithelial lymphocytes. The CD8 immunostaining could be
useful in the elderly patients, when a refractory celiac
disease (RCeD) is suspected [14,15,16,17,18,19,20,21-23].
STATEMENT 4. The pathological duodenal mucosa.
The histopathological features most commonly found in
CeD are villous atrophy, crypts hyperplasia, increased
number of IELs (25/100 epithelial cells). The IELs count
must be performed both in the apical portions and along
the side of the villi, incorrectly oriented biopsies with
aligned epithelial cells and using an anti-CD3
monoclonal antibody. We strongly recommend the use
of the classifications by Marsh and Corazza-Villanacci
to improve the standardization of the terminology.
[Grade of Evidence: 1]
The histopathological features of the duodenal mucosa in
the setting of CeD were classified by Marsh [24] with a
subsequent modification by Oberhuber [25]. However, a
modern consensus established that a cut-off of 25
IEL/100 enterocytes optimizes discrimination between
normal control and CeD biopsies [26]. To standardize the
terminology and to improve the diagnostic reproducibility,
a new histological classification has been proposed by
Corazza and Villanacci [27,28]. The two classifications are
summarized and compared in Table 2. Recently a
simplified classification with only two entities was
proposed [29]

Fig.1 An example of cellulose acetate filters with a
"clarinet beak-shaped cut. The adequate number of
oriented biopsies of the duodenum and stomach on the
filter.

STATEMENT 5. The histology report.
The Authors recommend listing the pathological
features found in the duodenal mucosa in the histology
report, avoiding the terms "celiac disease," "gluten
sensitivity/intolerance," "malabsorption." The use of
anti-CD3 immunostain is strongly advised, in
particular, in the non-atrophic cases. The use of
ambiguous terminology is strongly discouraged. [Grade
of Evidence: 3]
CeD diagnosis results from an overall clinical, serological,
and pathological assessment. The histology report should
provide a comprehensive description of the duodenal
mucosal lesions. It could be a descriptive report,
summarizing the microscopic findings with a final
diagnostic interpretation, or it could alternatively be in the
check-list format [30]. Regardless of the report type, the
pathological features should be listed, the terminology
should be straightforward, the terms ‘celiac disease’ or
lesion compatible with malabsorption/ gluten sensitivity’
avoided, as they may be misleading. Atrophy should be
graded, if present, as mild, moderate, and severe. The IELs
count is a diagnostic key-point. A number greater than
25/100 epithelial cells is considered pathological. In the
early phase of the disease, when the villi are present, the
presence of a pathological amount of IELs, without
architectural abnormalities in the duodenal mucosa, could
be the only feature suggesting CeD. Thus, we recommend
performing a CD3 immunostain. Application of the CD8
antibody could be useful in elderly patients when a
refractory celiac disease (RCeD) is suspected [31,32].
STATEMENT 6. The differential diagnosis.
Several clinical conditions share histopathological
features with CeD, most of all, the increased IELs count.
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Thus, we strongly recommend a careful examination of
the clinical setting. [Grade of Evidence: 2]
A condition of hypersensitivity to non-gluten components
of foods, including cereals, cow's milk, soy products, fish,
rice, and chicken, may be associated with increased IELs in
affected patients, without villous atrophy. In some
infections, such as in the Helicobacter Pylori-related
gastritis [33,34], Giardia Lamblia, or Cryptosporidium, the
duodenal mucosa shows an increased number of IELs
without architectural abnormalities. Moreover, several
drugs and autoimmune disorders produce the same
histology findings [35]. Other reported conditions
associated with an increased number of IELs include
Hashimoto thyroiditis, Graves' disease, rheumatoid
arthritis, psoriasis, multiple sclerosis, and systemic lupus
erythematosus. Common variable immune deficiency also
causes intestinal mucosal damage due to inflammation
and/or infections [36].
Furthermore, chronic inflammatory bowel diseases and
collagenous and lymphocytic colitis have been
concurrently associated with proximal small intestinal
intraepithelial lymphocytosis. Noteworthy, graft versus
host disease (GVHD) and other GVHD-like conditions
show an increased IELs count. However, the clinical
setting, the co-existence of both epithelial cell apoptosis,
and some degree of architectural disturbance in GVHD
allow proper microscopic interpretation [37]. In the
enteropathy-type T-cell lymphoma (ETTL), neoplastic
cells can be seen within a mildly atrophic or non-atrophic
duodenal mucosa during the pre-infiltrative (cryptic) phase

[38-41]. Flow-cytometry evaluation for <gamma>/<delta>
IELs may help differentiate gluten- from non-gluten
dependent conditions.[42]
Fig.2 A-B Non oriented biopsies H&E A 4X, B 20X; C-D
Oriented biopsies: here, it is possible to distinguish real
atrophy and count the real number of IELs (C, H&E 10X
and D, CD3 10X).
STATEMENT 7. The refractory celiac disease.
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RCeD requires that a diagnosis of CeD has been already
rendered, entailing a subsequent gluten-free diet. We
recommend performing immunostains for CD3 and
CD8 to differentiate RCeD1 from RCeD2 in biopsy
samples taken when the patient is on a strict GFD. The
use of the novel marker NKp46 could be considered.
Further differential diagnosis includes other diseases
mimicking CeD, such as autoimmune enteropathy and
olmesartan-associated
enteropathy.
[Grade
of
Evidence: 3]

Patients not responding to the gluten-free diet after 12
months may be suffering from RCeD. Two types of RCeD
have been described. In equivocal cases, a second
endoscopy and several biopsies are mandatory. The small
bowel lesions in RCeD1, as well as in RCeD2, can be
included in the Marsh classification criteria, with the
prevalence of Marsh lesion type III, although Marsh lesion
type II is possible. The presence of sub-epithelial collagen
formation (similar to that seen in collagenous sprue),
extending into the lamina propria with entrapment of
capillaries or other cellular elements, the increased subcryptal chronic inflammatory cells, and mucosal atrophy
with crypt hypoplasia are useful microscopic criteria for the
diagnosis of RCeD [43,44]. The presence of aberrant IELs
immunophenotype in RCeD2 differentiated in RCeD1 from
RCeD2.
Indeed,
RCeD1
shows
the
same
immunophenotype seen in CeD, with the majority of
lymphocytes expressing CD3, CD7, CD8, CD103, and
TCRβ. On the other hand, RCeD2 expresses CD103, CD7,
and cytoplasmic CD3, but not surface CD3, CD4, CD8, or
TCR-β. [45,47]. A diagnostic biomarker NKp46, belonging
to the NK receptors (NKRs), has been recently proposed to
differentiate RCD2 from RCD 1 since it was found to be
significantly more expressed by malignant RCD2 IELs than
normal IELs in CeD and RCD1 [48]. Some
histopathological features consistent with RCeD are shared
by other pathological conditions, such as the autoimmune
enteropathy, a rare disease having some overlap with CeD,
and olmesartan-associated enteropathy (an angiotensin II
receptor blocker). The latter may be associated with a
severe sprue-like enteropathy [49-50-51]. The clinical
course of CeD can be complicated by further pathological
conditions, namely ulcerative jejunitis (UJ) and ETTL,
affecting the clinical outcome and the overall survival. UJ
is a rare disease shown to evolve from pre-existing RCeD.
Generally, the ulceration extends through the full thickness
of the mucosa, with secondary vascular changes at the ulcer
base. Coexistent chronic inflammation, fibrosis, and
muscular hypertrophy, the latter responsible for the
stricture formation, can be found. The non-ulcerated
mucosa may display flattening, and villous atrophy along
with other CeD-like changes, such as crypt hyperplasia,
IELs infiltration, superficial enterocytes irregularity, and
mixed infiltrate composed by plasma cells, eosinophils, and
neutrophils, both adjacent to-and remote from-areas of
ulceration. Transmural inflammation and submucosal
edema are occasional, but lymphoid follicles, granulomas,
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or giant cells are usually absent. RCeD histological and
immunohistochemical features may also be seen [52-53].
UJ may evolve within the background of RCD as fullthickness ulceration of mucosa surrounded by villous
atrophy and CD-like changes. ETTL is assumed to derive
from IELs, and the aberrant immune phenotype seen in
RCeD2 IELs represents an early stage in the development
of overt lymphoma. Two distinct histological subtypes
have been recognized. Type 1 ETTL (ETTL-1) shows an
infiltrate of medium-sized cells containing round or angular
nuclei with prominent nucleoli and a moderate amount of
eosinophilic cytoplasm. In some cases, the tumor cells may
display marked pleomorphism, recalling anaplastic largecell lymphoma or Hodgkin's lymphoma. Type 2 ETTL
(ETTL-2) is rare and comprises a monomorphic population
of small cells with hyperchromatic nuclei and minimal
cytoplasm. In the intact/non-tumor mucosa, features of
CeD can be seen, including intraepithelial lymphocytosis.
The tumor cells in ETTL-1 express CD3 and CD7, but not
CD4, CD8, CD5, or CD56. The cells with an anaplastic
morphology show CD30 positivity. The IELs in the nonneoplastic mucosa have the same immunophenotype as in
RCeD2, UJ, and ETTL-1 (CD3+, CD4- ⁄ 8-, CD56-). In
contrast, the neoplastic cells in ETTL-2 show a CD3+,
CD8+, CD56+, CD4- pattern, and this profile is also seen
in the majority of adjacent IELs, with only a minor CD4/CD8- population [51,52,53,54,55,56,57]. NKp46 was also
detected in ETTL, highlighting its progression from RCD2
[48].

3.8. STATEMENT 8. Non-Celiac Gluten Sensitivity.
The Non-Celiac Gluten Sensitivity (NCGS) has been
associated with duodenal biopsies showing normal villi,
increased eosinophils in the lamina propria, and normal
IELs count, but with both a peculiar lymphocytic
arrangement in small intra-epithelial clusters and a
linear disposition in the deeper mucosa. In such
instances, a thorough clinical-pathological correlation is
strongly recommended. [Grade of Evidence: 3]
The histologic characteristics of NCGS are still under
investigation, ranging from normal histology to a slight
increase in the number of T lymphocytes in the superficial
epithelium of villi. Some authors describe a normal number
of T lymphocytes but a peculiar disposition of this cells in
a small "cluster" of 3-4 elements in the superficial
epithelium, as well as the linear disposition in the deeper
part of the mucosa together with an increased number of
eosinophils (>5/HPF) in lamina propria. Further studies are
needed to assess these findings as specific for NCGS
[58,59,60].

ABBREVIATIONS
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CeD: celiac disease; NCGS: non-celiac gluten
sensitivity; RCeD: refractory celiac disease; UJ: ulcerative
jejunitis, ETTL: enteropathy-type T-cell lymphoma,
TTGA: anti-transglutaminase antibodies; EmA: antiendomysium antibodies; AGA: anti-gliadin antibodies;
IELs: intra-epithelial lymphocytes; HP: Helicobacter
Pylori; GFD gluten free diet; NKRs: NK receptors; HPF:
high power fields.
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STATEMENTS

1
Methodological approach to
biopsy

At least four mucosal biopsies are recommended, and biopsy orientation is strongly
encouraged in order to avoid diagnostic pitfalls.

Serological
tests

The detection of TTGA titer (plus AGA in children younger than 2 years) is recommended.
The detection of AGA titer together with negative TTGA and EmA titers never qualify CeD
in adult patients and in children older than 2 years. The detection of the IgG class should be
limited to patients with selective IgA deficiency. The genetic test could support the
multidisciplinary diagnosis of CeD in selected cases.

2
and

genetic

3
Healthy duodenal mucosa

The healthy duodenal mucosa is characterized by a villus/crypt ratio more than 3/1. A
lymphocytic amount of more than 30 lymphocytes/100 epithelial cells has to be considered
as pathological. The IELs count must be performed both in the apical portions and along the
side of the villi, in perfectly oriented biopsies with aligned epithelial cells and using antiCD3 monoclonal antibody.

Pathological
mucosa

We strongly recommend the use of the classifications by Marsh and Corazza-Villanacci in
order to improve the standardization of the terminology.

4
duodenal

5
The histology report

We suggest to list the in the histology report all pathological features observed in the
duodenal mucosa consisting with Ced.

Differential diagnosis

Several clinical conditions share some histopathological features with CeD, most of all the
increased IELs count. Thus, we strongly recommend a careful examination of the clinical
setting.

Refractory Celiac Disease

RCeD requires that a diagnosis of CeD has been already rendered, entailing a subsequent
gluten-free diet. We recommend performing immunostains for CD3 and CD8 in order to
differentiate RCeD1 from RCeD2. The use of the novel marker NKp46 could be considered.
A further differential includes other disease mimicking CeD, such as autoimmune
enteropathy and Olmesartan-associated enteropathy.

6

7

8
NCGS

The NCGS may be suspected in duodenal biopsies characterized by normal villi, increased
eosinophils in the lamina propria and normal IELs count, but with both a peculiar
lymphocytic arrangement in small intra-epithelial clusters and a linear disposition in the
deeper mucosa. In such instances, a thorough clinical-pathological correlation is strongly
recommended.

Table 1. Main topics and statements for a correct gluten
intolerance diagnosis
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Corazza-Villanacci

Villanacci
Lesions

Lesions

Diagnostic Criteria

Lesions

Type I lesion

No architectural changes (villous/cript ratio preserved)

Grade A lesion

infiltrative

Increased IELs count (> 25/100 epithelial cells)

not atrophic

Type II lesion
hyperplastic

No architectural changes (villous/cript ratio preserved)
Crypt hyperplasia (mitoses > 1/crypt)

No architectural
changes (villous/cript
ratio preserved)
Increased IELs count (>
25/100 epithelial cells)

A
Non atrophic
type
No architectural
changes (villous/cript
ratio preserved)

Increased IELs count (> 25/100 epithelial cells)

Increased IELs count
(> 25/100 epithelial
cells)
Type III A lesion

Villous atrophy (mild degree)

Grade B1 lesion

destructive

Crypt hyperplasia (mitoses > 1/crypt)

partial atrophy

Increased IELs count (> 25/100 epithelial cells)

Villous atrophy (milsmoderate degree)

Type III B lesion

Villous atrophy (moderate degree)

destructive

Crypt hyperplasia (mitoses > 1/crypt)
Increased IELs count (> 25/100 epithelial cells)

Crypt hyperplasia
(mitoses > 1/crypt)
Increased IELs count
(> 25/100 epithelial
cells)

Type III C lesion

Villous atrophy (severe degree)

Grade B2 lesion

destructive

Crypt hyperplasia (mitoses > 1/crypt)

total atrophy

Increased IELs count (> 25/100 epithelial cells)

Villous atrophy
(severe degree)

B
Atrophic
Type
Villous atrophy (mildmoderate-severe
degree)
Crypt hyperplasia
(mitoses > 1/crypt)
Increased IELs count
(> 25/100 epithelial
cells)

Crypt hyperplasia
(mitoses > 1/crypt)
Increased IELs count
(> 25/100 epithelial
cells

Table 2 comparison among the current main
classifications of mucosal damage in CeD.
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